Skip to main content

Hi Alyssa,
Thank you so much for your comments. I think you nailed down some incredible points that really make you think. After doing a quick literature review there are some potential candidates for these drugs, but as you had mentioned they all have moderate quality evidence to suggest a lowered risk of serious AF. And, I agree with you, it does warrant these clinical trials moving forward even if a moderate improvement is the end goal. And to answer your question, are there any drugs that may be up and coming in the space, to my knowledge Dapaglidlozin is a potential candidate for this space [1].

Thank you so much for your great post, Alyssa.
Kyla

References:
[1] Okunrintemi V, Mishriky BM, Powell JR, Cummings DM. Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials. Diabetes Obes Metab. 2021 Jan;23(1):276-280. doi: 10.1111/dom.14211. Epub 2020 Oct 19. PMID: 33001548.

Name
Kyla Tozer

Plain text

  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.